This standard specification will provide a detailed description of the types of test samples needed to assess performance of synthetic opioid field screening chemical detectors and assays, including fentanyl and fentanyl-related compounds. Technologies that could utilize the standard include gas chromatography/mass spectrometry (GC/MS), mass spectrometry (MS), ion mobility spectrometry (IMS), Fourier transform infrared spectroscopy (FTIR), Raman spectroscopy, colorimetric assays, and immunoassays. Test sample amounts, concentrations/purity, and overall sample composition will be given including different test panels for fentanyl, fentanyl-related compounds, other synthetic and semi-synthetic opioids, synthesis precursors, other drugs, and diluents/cutting agents. The number of samples to be tested and the number of allowed test failures to achieve a given probability of detection and confidence level will also be given.
First responders and agencies at the federal, state and local level utilize various types of equipment and assays in the field to characterize unknown, potential dangerous samples that may be suspected of being drugs. However, the true performance of the equipment and assays used by agencies across the nation is largely uncharacterized with regards to diverse sample types and potentially interfering material (e.g., cutting agents) that could result in false positive results and subsequent negative/dangerous impacts to individuals and the public. This standard will provide a means to consistently and objectively test various types of equipment and assays used for detection of synthetic opioids and related chemical compounds in the field. The results of thorough testing of equipment and assays will enable a true understanding of their performance and potential weaknesses that will enable better informed procurement decisions and better knowledge of the use and limitations of different products, benefiting a wide range of end users (e.g., first responders, federal, state and local agencies involved with drug interdiction).
The title and scope are in draft form and are under development within this ASTM Committee.Back to Top
Negative Votes Need Resolution